Hospital-level care for acutely ill adults in the comfort of their own home.
Prescription software to enable early detection of heart failure exacerbation and augment guideline-directed use of heart failure medications.
Value proposition: • Reduces Length of Stay, 30-day rehospitalization rate and overall healthcare spending while improving quality of life and function in patients with heart failure
FDA 510(k) clearance for Biovitals® Analytics Engine and market authorization in the U.S. for BiovitalsHF® V1
Cloud-based Software for automated detection of over 15 types of cardiac arrhythmias
FDA 510(k) clearance for RhythmAnalytics® - A Software as a Service (SaaS) offering with scalable APIs to enable easy integration
Novel Deep Neural Network architecture trained on 4 Million EKGs to achieve highest degree of detection performance
Biovitals® Sentinel by Biofourmis allows for the continuous remote monitoring of critical biovitals and patient reported symptoms using Everion, an innovative new multi-sensor armband wearable.
Advanced AI/ML algorithms used to process the collected data and detect physiological change and predict events in various disease conditions, facilitating early intervention, and thereby dramatically improving outcomes of many traditional therapeutics.
Augments pain management by objective assessment of pain to guide personalized therapeutic decision-making
Proof-of-concept established in multiple pain types — cancer pain, post-orthopedic surgery
Two ongoing multi-center, clinical trials in post-operative pain and cancer pain
Prescription Software to continuously monitor and detect early signs of deterioration in oncology patients, pre- and post- treatment
Gaido enables you to prevent avoidable readmissions and helps spare your patients from developing infections, sepsis, dehydration and other conditions
Value proposition: Reduce Length of stay, 30-days rehospitalization and overall healthcare spending while improving quality of life and function in patients with cancer
Our modularized digital trial platform empowers patients and drives engagement while capturing real-time study data anytime, anywhere, from dynamic apps and connected devices
Our end-to-end platform provides a fully integrated suite of tools for digital clinical trials — remote passive monitoring using wearables, ePRO, eConsent, eCOA and eSource
Using our Biovitals® Analytics, we enable identification of novel patient-centric biomarkers as surrogate endpoints to achieve primary/secondary endpoints to speed up clinical trials
Our digital therapeutics portfolio consists of products that cover multiple therapeutic areas, including heart failure, acute coronary syndrome, COPD, oncology, and chronic pain.
See Life Sciences solutions
PRODUCT/
|
THERAPEUTIC AREA |
Research & Translation | Pilot | FDA Presub | Pivotal | FDA Authorization | Commercial |
|---|---|---|---|---|---|---|---|
| PLATFORM | |||||||
Biovitals® Analytics* |
Disease Agnostic |
||||||
RhythmAnalytics®* |
Cardiovascular |
||||||
| CARDIOMETABOLIC | |||||||
Biovitals® V1 |
Heart Failure |
||||||
Biovitals® V2 (BF110) |
Heart Failure |
||||||
BiovitalsCAD (BF111) |
Coronary Artery Disease |
||||||
BF112 |
Atrial Fibrillation / Obstructive Sleep Apnea |
||||||
| ONCOLOGY & PAIN | |||||||
Gaido* |
Solid Tumor |
||||||
BF130 |
Solid Tumor |
||||||
BF140 |
Pain |
||||||
PLATFORM |
RESEARCH & TRANSLATION | PILOT | FDA PRESUB | PIVOTAL | FDA AUTH. | COMMERCIAL |
|---|---|---|---|---|---|---|
Biovitals® Analytics*Disease Agnostic |
||||||
RhythmAnalytics®*Cardiovascular |
||||||
CARDIOMETABOLIC |
BiovitalsHF® V1Heart Failure |
|||||
BiovitalsHF® V2 (BF110)Heart Failure |
||||||
BiovitalsCAD (BF111)CAD |
||||||
BFF112AF/OSA |
||||||
ONCOLOGY & PAIN |
Gaido*Solid Tumor |
|||||
BF130Solid Tumor |
||||||
BF140Pain |
Internal product candidates
Partnered/In-licensing product candidates
**Products have also obtained regulatory approval in countries outside the U.S.